# US 2022/0033455 A1 · Il-15-based fusions to il-7 and il-21

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033455 A1
- Document ID: US20220033455A1
- Status: Published application
- Kind: A1
- Application number: 17/504,100
- Filed: 2021-10-18
- Published: 2022-02-03
- Earliest claimed: 2017-08-28
- Assignees: Altor BioScience Corporation
- Applicants: Altor Bioscience, LLC
- Inventors: Hing C. Wong
- Web page: https://patentgrep.com/patent/US20220033455A1

## CPC

- C07K 14/5443: {IL-15}
- A21D 8/047: {with yeasts}
- A61K 38/2086: {IL-13 to IL-16}
- A61P 37/04: Immunostimulants
- C07K 14/54: Interleukins [IL]
- C07K 14/5418: {IL-7}
- C07K 14/7155: {for interleukins [IL]}
- C12N 15/81: for yeasts
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12Y 302/01002: Beta-amylase (3.2.1.2)
- C12Y 302/01033: Amylo-alpha-1,6-glucosidase (3.2.1.33)
- C12Y 302/0106: Glucan 1,4-alpha-maltotetraohydrolase (3.2.1.60)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A21D: TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS (preservation of flour or dough before baking A23B40/00; preservation of bakery products A23B45/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-7 or IL-21.

## Claims

### Claim at position 1

1-60. (canceled)

### Claim 61

A soluble protein complex comprising:
a first fusion protein comprising a segment substantially identical to SEQ ID NO: 10 (IL-7) and a segment substantially identical to SEQ ID NO:8 (IL-15RαSu/Fc); and
a second fusion protein comprising a segment substantially identical to SEQ ID NO:6 (IL-21) and a segment substantially identical to SEQ ID NO: 12 (IL-15N72D),
wherein the first and second soluble proteins are covalently linked by a disulfide bond to form the soluble fusion protein complex.

### Claim 62 (depends on 61)

The soluble protein complex of claim 61, wherein the IL-17 segment is attached to the N-terminus of the IL-15RαSu/Fc.

### Claim 63 (depends on 61)

The soluble protein complex of claim 61, wherein the IL-17 segment is attached to the C-terminus of the IL-15RαSu/Fc.

### Claim 64 (depends on 62)

The soluble protein complex of claim 62, wherein the IL-21 segment is attached to the N-terminus of the IL-15N72D.

### Claim 65 (depends on 62)

The soluble protein complex of claim 62, wherein the IL-21 segment is attached to the C-terminus of the IL-15N72D.

### Claim 66 (depends on 63)

The soluble protein complex of claim 63, wherein the IL-21 segment is attached to the N-terminus of the IL-15N72D.

### Claim 67 (depends on 63)

The soluble protein complex of claim 63, wherein the IL-21 segment is attached to the C-terminus of the IL-15N72D.

### Claim 68 (depends on 64)

The soluble protein complex of claim 64, wherein the IL-21 segment consists of SEQ ID NO:6, the IL-15RαSu/Fc consists of SEQ ID NO:8, the IL-17 segment consists of SEQ ID NO: 10, and the IL-15N72D segment consists of SEQ ID NO: 12.

### Claim 69 (depends on 65)

The soluble protein complex of claim 65, wherein the IL-21 segment consists of SEQ ID NO:6, the IL-15RαSu/Fc consists of SEQ ID NO:8, the IL-17 segment consists of SEQ ID NO: 10, and the IL-15N72D segment consists of SEQ ID NO: 12.

### Claim 70 (depends on 66)

The soluble protein complex of claim 66, wherein the IL-21 segment consists of SEQ ID NO:6, the IL-15RαSu/Fc consists of SEQ ID NO:8, the IL-17 segment consists of SEQ ID NO: 10, and the IL-15N72D segment consists of SEQ ID NO: 12.

### Claim 71 (depends on 67)

The soluble protein complex of claim 67, wherein the IL-21 segment consists of SEQ ID NO:6, the IL-15RαSu/Fc consists of SEQ ID NO:8, the IL-17 segment consists of SEQ ID NO: 10, and the IL-15N72D segment consists of SEQ ID NO: 12.

### Claim 72 (depends on 61)

The soluble protein complex of claim 61, wherein the first fusion protein is covalently linked to the second fusion protein by a disulfide bond.